BETHESDA, Md.--(BUSINESS WIRE)-- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that it will host a conference call and audio webcast to review its third quarter 2010 results on Tuesday, November 9, 2010, at 8:30 AM ET.
To participate in the conference call, please dial 866-713-8395 (domestic) or 617-597-5309 (international) and reference the access code 11269684. The presentation will be available via webcast in the Investor Relations section of the Micromet website at www.micromet.com.
A replay of the call will be available from 11:30 AM ET on November 9, 2010 until midnight ET on December 9, 2010. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and reference the access code 63331845. The archived webcast will be available for 30 days at www.micromet.com.
About Micromet, Inc.
Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. The Company’s lead product candidate blinatumomab (MT103) is currently the subject of a European pivotal trial in patients with minimal residual disease positive acute lymphoblastic leukemia. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Bayer Schering Pharma, Boehringer Ingelheim, MedImmune, Merck Serono, Nycomed and sanofi-aventis. Additional information can be found at www.micromet.com.
Director, Corporate Communications
KEYWORDS: United States North America Maryland
INDUSTRY KEYWORDS: Health Biotechnology Oncology Pharmaceutical Research Science